Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

Published:2012-10 Issue:20 Volume:20 Page:6144-6153
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Chen Kuen-Feng,Pao Kuan-Chuan,Su Jung-Chen,Chou Yi-Chieh,Liu Chun-Yu,Chen Hui-Ju,Huang Jui-Wen,Kim InKi,Shiau Chung-Wai

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference23 articles.

1. Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A

2. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation

3. CIP2A expression is increased in prostate cancer

4. CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis

5. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases;Medicina;2023-08-26

2. Design, synthesis, and molecular docking studies of novel quinoxaline derivatives as anticancer agents;Chemical Biology & Drug Design;2023-04-24

3. From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer;Frontiers in Genetics;2023-02-24

4. Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma IDH Wildtype;Cancers;2022-10-25

5. TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1;Cancer Letters;2021-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3